ArticleDiscover oncology2025
The effects of coagulation factors on the risk of lung cancer: a Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecent research increasingly highlights a strong correlation between systemic hypercoagulability and the risk of lung cancer (LC). However, whether this relationship is causal or merely coincidental remains uncertain. To address this, a Mendelian randomization (MR) analysis was undertaken to explore the connections between coagulation factors and LC.
methodsGenome-wide association study (GWAS) summary statistics for LC subtypes were retrieved from European ancestry meta-analyses via the IEU Open GWAS project, encompassing three distinct histological subtypes: squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. Bidirectional two sample MR analyses were performed using genome-wide significant single nucleotide polymorphisms (SNPs) as instrumental variables. To evaluate bidirectional causality between 14 coagulation factors and LC, including its subtypes, we applied multiple analytical methods, including inverse variance weighting (IVW), MR-Egger, weighted median, weighted mode, and simple mode.
resultsThe IVW analysis revealed distinct causal associations between coagulation factors and LC subtypes. Elevated plasma levels of factor X (FX) demonstrated a significant risk effect for squamous cell carcinoma [odds ratio (OR) = 1.143, P = 0.006], while increased FVIII concentrations were positively associated with adenocarcinoma susceptibility (OR = 1.161, P = 0.049). Conversely, higher A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity exhibited a protective effect against adenocarcinoma development (OR = 0.781, P = 0.029). No statistically significant relationships were identified between any coagulation factors and small cell carcinoma.
conclusionLeveraging GWAS data derived from large-scale population cohorts, our MR analysis revealed significant causal effects of FX, FVIII, and ADAMTS13 on LC risk. These findings suggest that these coagulation factors are involved in the development of LC and may represent potential therapeutic targets for the management of this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.